Optimization of antigen-specific CD8+ T cell activation conditions for infectious diseases including COVID-19

Chanchan Xiao; Congling Qiu; Jieping Deng; Jiezhou Ye; Lijuan Gao; Jun Su; Oscar Junhong Luo; Pengcheng Wang; Guobing Chen

STAR Protocols (Sep 2021)

Optimization of antigen-specific CD8+ T cell activation conditions for infectious diseases including COVID-19

Chanchan Xiao,
Congling Qiu,
Jieping Deng,
Jiezhou Ye,
Lijuan Gao,
Jun Su,
Oscar Junhong Luo,
Pengcheng Wang,
Guobing Chen

Affiliations

Chanchan Xiao: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China
Congling Qiu: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China; Affiliated Huaqiao Hospital, Jinan University, Guangzhou, China
Jieping Deng: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China
Jiezhou Ye: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China
Lijuan Gao: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China
Jun Su: Affiliated Huaqiao Hospital, Jinan University, Guangzhou, China
Oscar Junhong Luo: Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China; Department of Systems Biomedical Sciences, School of Medicine, Jinan University, Guangzhou, China
Pengcheng Wang: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China; Corresponding author
Guobing Chen: Department of Microbiology and Immunology, Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, Guangzhou, China; Affiliated Huaqiao Hospital, Jinan University, Guangzhou, China; Corresponding author

Journal volume & issue: Vol. 2, no. 3
p. 100789

Abstract

Read online

Summary: Here, we describe the use of the artificial antigen-presenting cell (aAPC) system for the verification of T-cell epitopes. We purify and activate CD8+ T cells from blood samples from HLA-A2 that are negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). CD8+ T cells are combined with peptide-loaded T2-A2 cells, which are then stained with a SARS-CoV-2-specific MHC-1 tetramer to identify specific HLA-A2-restricted T-cell epitopes. The use of aAPC and healthy donors means that only BSL2 lab conditions are needed.For details of the use and implementation of this protocol, please refer to Deng et al. (2021).

Published in STAR Protocols

ISSN: 2666-1667 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Science (General)
Website: https://star-protocols.cell.com/

About the journal

Abstract

Keywords